Monoclonal antibody · Antagonist of RANKL (TNFSF11) · developed by Alvotech Swiss
AVT03 (denosumab) is a recombinant fully human IgG2 monoclonal antibody that binds RANKL, a protein that drives osteoclast formation and activity. It is given as a subcutaneous injection and is studied in postmenopausal osteoporosis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05395091 | Phase 3 | Osteoporosis, Postmenopausal | Completed | ALVO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Osteoporosis, Postmenopausal
Updated Oct 11, 2026. Something wrong or missing? Report it on the ALVO page.
See ALVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ALVO catalysts and pipeline →